ALS Genetics: Gains, Losses, and Implications for Future Therapies
Open accessAbstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder caused by the loss of motor neurons from the brain and spinal cord. The ALS community has made remarkable strides over three decades by identifying novel familial mutations, generating animal models, elucidating molecular mechanisms, and ultimately developing promising new therapeutic approaches. Some of these approaches reduce the expression of mutant genes and are in human clinical trials, highlighting the need to carefully consider the normal functions of these genes and potential contribution of gene loss-of-function to ALS. Here, we highlight known loss-of-function mechanisms underlying ALS, potential consequences of lowering levels of gene products, and the need to consider both gain and loss of function to develop safe and effective therapeutic strategies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Many ALS genetic mutations are associated with immune response, such as C9orf72, TBK1, CYLD, OPTN, and PGRN.
“Many of the genetic mutations are associated with immune response, such as C9orf72, TBK1, CYLD, OPTN, PGRN, and so on.85,272”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [272]
The Introduction sections on C9ORF72 and OPTN and TBK1 link these ALS genes to immune dysregulation or innate immune function. The GRN section says PGRN regulates inflammatory responses and that GRN mutations have been found in ALS patients. The paper does not substantiate CYLD as an example; a search for CYLD found no matching discussion in our copy (page numbers unavailable). (LLM, conf=0.88)
Experimental — accuracy not yet measuredMutations in genes such as SOD1, TDP-43, and FUS lead to the formation of toxic protein aggregates specifically within motor neurons in ALS.
“Mutations in genes such as SOD1, TDP-43, and FUS lead to the formation of toxic protein aggregates specifically within motor neurons.192”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [192]
The most common genes identified in clinical practice include SOD1, C9ORF72, TARDBP, FUS, and OPTN/TDP-43.
“The most common genes identified in clinical practice include SOD1, C9ORF72, TARDBP, FUS, and OPTNTD-P43 (55–57, 73, 74).”
From Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis (2023) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 284 · Cited by 370
- Authors
- Kim, G., Gautier, O., Tassoni-Tsuchida, E., Ma, X. R., & Gitler, A. D.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Gitler, Aaron D.
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 108
- Issue
- 5
- Pages
- 822-842
- ISSN
- 0896-6273 (ISSN-L)
- PMC
- PMC7736125
- OpenAlex
- W3084494434
- Cited by
- 370
- References
- 284
- Citations by year
- 2026: 26 · 2025: 57 · 2024: 76 · 2023: 76 · 2022: 70 · 2021: 63 · 2020: 2
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- amyotrophic lateral sclerosis, ALS genetics, loss-of-function mechanism, gain-of-function mutations, therapeutic target, motor neuron degeneration, neurodegeneration, animal models of ALS
- MeSH terms
- Superoxide Dismutase-1, Loss of Function Mutation, Gain of Function Mutation, C9orf72 Protein, Amyotrophic Lateral Sclerosis, Animals, Forecasting, Humans, Genetic Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review